{"id":31967,"date":"2014-09-24T10:00:14","date_gmt":"2014-09-24T14:00:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31967"},"modified":"2014-09-24T10:00:14","modified_gmt":"2014-09-24T14:00:14","slug":"celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967","title":{"rendered":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/24\/2014 (wallstreetpr) \u2013 <strong>Celgene Corporation (NASDAQ:CELG)<\/strong> could upset companies like <strong>AbbVie Inc (NYSE:ABBV)<\/strong>,\u00a0<strong>Amgen, Inc. (NASDAQ:AMGN)<\/strong> and <strong>Pfizer Inc. (NYSE:PFE)<\/strong>, which are currently minting hefty money through their psoriasis injections currently selling in the market. Celgene Corporation (NASDAQ:CELG) reported on Tuesday that it has received the approval from the Food and Drug Administration for Otezla, a pill to treat moderate to severe psoriasis.<\/p>\n<p style=\"text-align: justify;\"><strong>Billion Dollar Sales<\/strong><\/p>\n<p style=\"text-align: justify;\">It is an important landmark for\u00a0Celgene Corporation (NASDAQ:CELG) to enter a billion dollar worth of market space as nearly 7.5 million Americans suffer from the disease, which causes redness and scaly patches on the skin. Currently, AbbVie Inc (NYSE:ABBV),\u00a0Amgen, Inc. (NASDAQ:AMGN) and\u00a0<strong>Pfizer Inc. (NYSE:PFE)<\/strong> are the three main companies that have treatments floated in the market, but they have a solid contender in the space now. As per a bloomberg report, Celgene&#8217;s Otezla could bring $1.03 billion of sales by the year 2017. Section cheif of dermatology, M. Shane Chapman from Dartmouth-Hitchcock Medical Center said that Celgene&#8217;s Otezla is a new treatment, which is a welcome development from patients, who do not find the current treatments adequate and are look out on alternative treatment. He added that Otezla has an advantage over other treatments as it has not to go through routine laboratory observation and thus, could become an attractive option for patients.<\/p>\n<p style=\"text-align: justify;\"><strong>Other Diseases<\/strong><\/p>\n<p style=\"text-align: justify;\">There is no stopping for Celgene Corporation (NASDAQ:CELG) as the company is testing Otezla for other indications such as rheumatoid arthritis and ankylosing spondylitis. In June, the company said that the drug did not return significant results for ankylosing spondylitis, but they will continue to find out other diseases that are treatable with the drug. Earlier this year, the company has already received approval from the FDA for using Otezla to treat psoriatic arthritis, present in nearly 30% of people in America.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/24\/2014 (wallstreetpr) \u2013 Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV),\u00a0Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":18676,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[1593,2831,2860,9623,1520,2861,1592,993,2745],"stock_ticker":[],"class_list":["post-31967","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-abbvie-inc-nyseabbv","tag-amgen-inc-nasdaqamgn","tag-celgene-corporation-nasdaqcelg","tag-m-shane-chapman","tag-nasdaqamgn","tag-nasdaqcelg","tag-nyseabbv","tag-nysepfe","tag-pfizer-inc-nysepfe","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/24\/2014 (wallstreetpr) \u2013 Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV),\u00a0Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-24T14:00:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors\",\"datePublished\":\"2014-09-24T14:00:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"keywords\":[\"AbbVie Inc. (NYSE:ABBV)\",\"Amgen Inc. (NASDAQ:AMGN)\",\"Celgene Corporation (NASDAQ:CELG)\",\"M. Shane Chapman\",\"NASDAQ:AMGN\",\"NASDAQ:CELG\",\"NYSE:ABBV\",\"NYSE:PFE\",\"Pfizer Inc (NYSE:PFE)\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\",\"name\":\"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"datePublished\":\"2014-09-24T14:00:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"width\":870,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967","og_locale":"en_US","og_type":"article","og_title":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR","og_description":"Boston, MA 09\/24\/2014 (wallstreetpr) \u2013 Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV),\u00a0Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-24T14:00:14+00:00","og_image":[{"width":870,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors","datePublished":"2014-09-24T14:00:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","keywords":["AbbVie Inc. (NYSE:ABBV)","Amgen Inc. (NASDAQ:AMGN)","Celgene Corporation (NASDAQ:CELG)","M. Shane Chapman","NASDAQ:AMGN","NASDAQ:CELG","NYSE:ABBV","NYSE:PFE","Pfizer Inc (NYSE:PFE)"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967","url":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967","name":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","datePublished":"2014-09-24T14:00:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","width":870,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-could-turn-things-upside-down-for-psoriasis-drug-competitors-31967#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31967"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31967\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18676"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31967"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}